Skip to content

A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications

A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00645125
Enrollment
154
Registered
2008-03-27
Start date
2003-01-31
Completion date
Unknown
Last updated
2008-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

pediatric taste test, antibiotic taste test, cefdinir, amoxicillin

Brief summary

To compare the taste and smell acceptability scores of cefdinir (Omnicef) versus amoxicillin oral antibiotic suspension medications in pediatric subjects. It is designed to determine if Omnicef or amoxicillin is preferred to the other with regard to taste or smell.

Detailed description

The Primary Purpose for the study is Other. Per ClinicalTrials.gov, more information regarding the primary purpose is described here; the primary purpose for the study is to determine whether cefdinir possesses preferred taste and smell characteristics when compared to amoxicillin, a pediatric taste test.

Interventions

2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL

DRUGamoxicillin

2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL

Sponsors

Abbott
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
4 Years to 8 Years
Healthy volunteers
Yes

Inclusion criteria

* Female or male child age 4 through 8 years in good general health. * Minimum weight of 16.3 kg (36 lb). * Willing to comply with appropriate instructions provided to complete the study. * Written informed consent from parent/legal guardian.

Exclusion criteria

* Current medical condition, that in the opinion of the Investigator or designee, could interfere with the ability to discriminate taste (e.g., common cold, sinus infection, bronchial infection, etc.). * History of allergic reaction to cefdinir, prescription (e.g. penicillins or cephalosporins) and/or OTC medications, and/or food products. * History of significant medical condition (e.g., GI disorders, hematological or bleeding disorders, renal or hepatic diseases). * Use of any oral medication, vitamins or herbal supplements within 6 hours prior to tasting. * Temperature \> than 99.2°F. * Participation in a clinical or marketing research study within the past 3 months. * Sibling of another subject on the study, or living in the same household as another subject that has participated in a clinical or marketing research study within the past 3 months. * Family member or close friend employed by an advertising agency, market research company and/or a company that processes or manufacturers medical or health care products.

Design outcomes

Primary

MeasureTime frame
Taste and smell acceptability assessment2 hours

Secondary

MeasureTime frame
Adverse events assessment72 hours with follow-up to a satisfactory conclusion
Concomitant medications72 hours
Vital signs2 hours
Any clinically abnormal observations2 hours with follow-up to a satisfactory conclusion

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026